Pharmaceutical News lan Artikel

Meh Katelu Apotek Eceran AS Wis Ditutup Wiwit 2010

Illinois, Maine, Mississippi, New York, Pennsylvania, Rhode Island lan Vermont. Ing kana, luwih saka setengah kabupaten ngalami penurunan net ing apotek. Ireng,

E. Wabah Coli Disambung karo McDonald's Quarter Pounders Diumumake

kondisi sing bisa micu gagal ginjel, miturut CDC.Informasi luwih lengkap CDC nduweni luwih akeh babagan E. coli.SUMBER US Food and Drug Administration, kesehatan

Zepbound Bests Wegovy kanggo Bobot Mundhut ing Trial Anyar

Zepbound, obat nyuda bobot GLP-1 anyar saka Eli Lilly Co., wis ngluwihi pesaing utama, Wegovy, ing uji klinis sing didanai dening Lilly. Diwenehi increa

Soleno Therapeutics Ngumumake Perpanjangan Periode Review FDA kanggo Tablet Rilis Lengkap DCCR (Diazoxide Choline) ing Sindrom Prader-Willi

Satsuma Pharmaceuticals lan SNBL Nampa Penerimaan FDA NDA Resubmission STS101 kanggo Perawatan Akut Migrain Kanthi utawa Tanpa Aura

Aquestive Therapeutics Ngumumake Umpan Balik Positif FDA lan Negasake Pandhuan Pangiriman NDA kanggo Film Sublingual Anafilm (epinefrin)

Aquestive Therapeutics, Inc. (NASDAQ AQST), perusahaan farmasi ngembangake obat-obatan kanggo ningkatake urip pasien liwat sc inovatif.

Syros Ngumumake Data Topline saka Uji Coba SELECT-MDS-1 Phase 3 Tamibarotene ing Sindrom Myelodysplastic Berisiko Tinggi kanthi Ekspresi Gen RARA

Syros Pharmaceuticals (NASDAQ SYRS), perusahaan biofarmasi sing setya ningkatake standar perawatan anyar kanggo perawatan garis ngarep saka hematologic maligna

FDA Nyetujoni Yesintek (ustekinumab-kfce), Biosimilar to Stelara

Lantern Pharma's Investigational Drug-Candidate, LP-184, Nampa Sebutan Fast Track Kapindho saka FDA kanggo Perawatan Kanker Payudara Negatif Tiga (TNBC)

Lantern Pharma Inc. (NASDAQ LTRN), perusahaan intelijen buatan (AI) sing darmabakti kanggo ngembangake terapi kanker lan ngowahi biaya, kecepatan, lan timelin.

FDA Menehi Penunjukan Terapi Terobosan kanggo Sacituzumab Tirumotecan (sac-TMT) kanggo Perawatan Pasien Tertentu Kanthi Kanker Paru-Paru Sel Non-Small Nonsquamous Nonsquamous sing Diobati Sadurunge Kanthi Mutasi EGFR

Merck (NYSE MRK), sing dikenal minangka MSD ing njaba Amerika Serikat lan Kanada, dina iki ngumumake yen US Food and Drug Administration (FDA) wis menehi Breakthroug.